| Catalog Number: | 973-MSM7 |
|---|---|
| Reactivity: | |
| Gene: | |
| Host: |
Trial Size Available
Carrier-Free Available
Formalin-fixed, paraffin-embedded human Tonsil stained with CD79a Monoclonal Antibody (HM57).
Western Blot Analysis of Raji cell lysate using CD79a Monoclonal Antibody (HM57).
SDS-PAGE Analysis of Purified CD79a Monoclonal Antibody (HM57). Confirmation of Purity and Integrity of Antibody.
Flow Cytometric Analysis of Raji cells using CD79a Monoclonal Antibody (HM57) followed by Goat anti-Mouse IgG-CF488 (Blue); Isotype Control (Red).
Immunofluorescence Analysis of PFA-fixed Raji cells labeling CD79a with CD79a Monoclonal Antibody (HM57) followed by Goat anti-Mouse IgG-CF488 (Green). The nuclear counterstain is Reddot (Red)
| Document Name | |
|---|---|
| Datasheet | Download Here |
| Material Safety Data Sheet | Download Here |
| Applications | Tested Dilutions | Protocol | Note |
|---|---|---|---|
| Flow Cytometry (Flow) | 1-2ug/million cells | Flow Cytometry Protocol | |
| Immunofluorescence (IF) | 1-3ug/ml | ||
| Immunohistochemistry (IHC) | 1-2ug/ml | IHC Protocol | 30 min at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes |
| Western Blot (WB) | 2-4ug/ml | Western Blot Protocol |
1
1
3
5
3
6
3
A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.
Should a NeoBiotechnologies antibody not meet the experimental expectations outlined on our website or datasheet, please contact our Technical Support. We unconditionally guarantee our product.
Our team of scientists are ready to help you with expert recommendations or technical assistance related to applications or product use.
Information
© 2026 NeoBiotechnologies. All Rights Reserved.
Monday-Friday: 8:00am – 8:00pm Pacific Time
